Answers are grounded in this paper and cite their sources.
Obesity is a major global health problem and the current pharmacological treatments for obesity though have short-term efficacy often cause side effects and rapid weight regain after discontinuation, highlighting the need for more durable, mechanism-based therapies. Leptin plays a significant role in appetite regulation and energy balance through activation of the long-form leptin receptor (LEPR) and downstream signalling pathways. In most individuals with obesity, however, chronic hyperleptinemia and hypothalamic inflammation lead to leptin resistance, blunting these satiety signals. Leptin receptor overlapping transcript (LEPROT) has emerged as a key negative regulator of leptin signalling, controlling LEPR surface availability and thereby limiting leptin sensitivity. Accumulating evidence from animal and emerging human studies suggests that the transcript upregulation contributes to leptin resistance, hyperphagia, and metabolic dysfunction, whereas transcript downregulation or knockout can enhance leptin responsiveness. This review synthesizes current knowledge on leptin signalling and LEPROT's role in leptin resistance and its potential as a therapeutic target for obesity. We highlight the need for tissue-specific, pathway-selective regulation and future development of pharmacological tools and biomarkers to guide future clinical translation.
No takes yet. Share an insight, caveat, or question.
Senthilvel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: